Watch for the anti-malaria drug and HIV drugs to be possible cures. Then we're off again to the Stars.
Yes that is the 2nd research path, better treatment while we work on a vaccine..
Better treatment doesn't need to be perfect, and can use existing drugs....
Once the Coronavirus bad news settles down, we are back to valuing companies on future earnings...
In the meantime having a hefty pile of cash in the bank to ride out the storm helps...
I still think it is technically possible for Tesla to not overly deplete cash too much while making a moderate loss...
Q4 2019 - $930M increase in our cash and cash equivalents in Q4 to $6.3B,
$359M GAAP operating income; 4.9% operating margin in Q4
Q1 2019 - We ended the quarter with $2.2 billion of cash and cash equivalents, a $1.5 billion reduction from the end of 2018.
- This reduction was driven by a $920 million convertible bond repayment and an increase in the number of vehicles in transit to customers at the end of Q1.
- GAAP operating loss of $522M, GAAP net loss of $702M, including $188M of non-recurring charges
So for Q1 2020, I don't think there is any convertible bond that needs repayment?
Vehicles in transit will increase as inventory was low at the end of Q4 and virus shutdowns will complicate delivery logistics..
It helps to put down some numbers otherwise it is all "the sky is falling".....
So 500M cash reduction is about of the worst I expect for Q1 2020, unless there is a significant increase in Capex.
Capex was $280M Q1 2019..
I would suggest keeping Capex in a separate category, as Tesla can slow that a bit if needed.
So in round terms with $8B in the bank and cash reducing by .5B per quarter even this negative scenario gives Tesla 16 quarters of survival so some insurance if future quarters are even worse.
If people are expecting worse than 0.5B cash reduction each quarter, it would be good to know why...